The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Small Molecule Targeted Anti-cancer Drug Market Research Report 2024
Synopsis
The global Small Molecule Targeted Anti-cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Small Molecule Targeted Anti-cancer Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Small Molecule Targeted Anti-cancer Drug.
Report Scope
The Small Molecule Targeted Anti-cancer Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Small Molecule Targeted Anti-cancer Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Small Molecule Targeted Anti-cancer Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astrazeneca
Novartis
Millennium Pharmaceuticals
Bayer
Exelixis
Abbvie
Boehringer-Ingelheim
Eisai
Pfizer
Bristol-Myers Squibb
Roche
Bettapharma
Segment by Type
EGFR
ALK
Bcr-Abl
Others
Segment by Application
Liver Cancer
Colorectal Cancer
Lung Cancer
Gastric Cancer
Breast Cancer
Esophageal Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Small Molecule Targeted Anti-cancer Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Small Molecule Targeted Anti-cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Small Molecule Targeted Anti-cancer Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Small Molecule Targeted Anti-cancer Drug.
Report Scope
The Small Molecule Targeted Anti-cancer Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Small Molecule Targeted Anti-cancer Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Small Molecule Targeted Anti-cancer Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astrazeneca
Novartis
Millennium Pharmaceuticals
Bayer
Exelixis
Abbvie
Boehringer-Ingelheim
Eisai
Pfizer
Bristol-Myers Squibb
Roche
Bettapharma
Segment by Type
EGFR
ALK
Bcr-Abl
Others
Segment by Application
Liver Cancer
Colorectal Cancer
Lung Cancer
Gastric Cancer
Breast Cancer
Esophageal Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Small Molecule Targeted Anti-cancer Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Small Molecule Targeted Anti-cancer Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 EGFR
1.2.3 ALK
1.2.4 Bcr-Abl
1.2.5 Others
1.3 Market by Application
1.3.1 Global Small Molecule Targeted Anti-cancer Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Liver Cancer
1.3.3 Colorectal Cancer
1.3.4 Lung Cancer
1.3.5 Gastric Cancer
1.3.6 Breast Cancer
1.3.7 Esophageal Cancer
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Small Molecule Targeted Anti-cancer Drug Market Perspective (2019-2030)
2.2 Small Molecule Targeted Anti-cancer Drug Growth Trends by Region
2.2.1 Global Small Molecule Targeted Anti-cancer Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Small Molecule Targeted Anti-cancer Drug Historic Market Size by Region (2019-2024)
2.2.3 Small Molecule Targeted Anti-cancer Drug Forecasted Market Size by Region (2025-2030)
2.3 Small Molecule Targeted Anti-cancer Drug Market Dynamics
2.3.1 Small Molecule Targeted Anti-cancer Drug Industry Trends
2.3.2 Small Molecule Targeted Anti-cancer Drug Market Drivers
2.3.3 Small Molecule Targeted Anti-cancer Drug Market Challenges
2.3.4 Small Molecule Targeted Anti-cancer Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Small Molecule Targeted Anti-cancer Drug Players by Revenue
3.1.1 Global Top Small Molecule Targeted Anti-cancer Drug Players by Revenue (2019-2024)
3.1.2 Global Small Molecule Targeted Anti-cancer Drug Revenue Market Share by Players (2019-2024)
3.2 Global Small Molecule Targeted Anti-cancer Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Small Molecule Targeted Anti-cancer Drug Revenue
3.4 Global Small Molecule Targeted Anti-cancer Drug Market Concentration Ratio
3.4.1 Global Small Molecule Targeted Anti-cancer Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Small Molecule Targeted Anti-cancer Drug Revenue in 2023
3.5 Small Molecule Targeted Anti-cancer Drug Key Players Head office and Area Served
3.6 Key Players Small Molecule Targeted Anti-cancer Drug Product Solution and Service
3.7 Date of Enter into Small Molecule Targeted Anti-cancer Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Small Molecule Targeted Anti-cancer Drug Breakdown Data by Type
4.1 Global Small Molecule Targeted Anti-cancer Drug Historic Market Size by Type (2019-2024)
4.2 Global Small Molecule Targeted Anti-cancer Drug Forecasted Market Size by Type (2025-2030)
5 Small Molecule Targeted Anti-cancer Drug Breakdown Data by Application
5.1 Global Small Molecule Targeted Anti-cancer Drug Historic Market Size by Application (2019-2024)
5.2 Global Small Molecule Targeted Anti-cancer Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Small Molecule Targeted Anti-cancer Drug Market Size (2019-2030)
6.2 North America Small Molecule Targeted Anti-cancer Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Small Molecule Targeted Anti-cancer Drug Market Size by Country (2019-2024)
6.4 North America Small Molecule Targeted Anti-cancer Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Small Molecule Targeted Anti-cancer Drug Market Size (2019-2030)
7.2 Europe Small Molecule Targeted Anti-cancer Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Small Molecule Targeted Anti-cancer Drug Market Size by Country (2019-2024)
7.4 Europe Small Molecule Targeted Anti-cancer Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Small Molecule Targeted Anti-cancer Drug Market Size (2019-2030)
8.2 Asia-Pacific Small Molecule Targeted Anti-cancer Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Small Molecule Targeted Anti-cancer Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Small Molecule Targeted Anti-cancer Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Small Molecule Targeted Anti-cancer Drug Market Size (2019-2030)
9.2 Latin America Small Molecule Targeted Anti-cancer Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Small Molecule Targeted Anti-cancer Drug Market Size by Country (2019-2024)
9.4 Latin America Small Molecule Targeted Anti-cancer Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Small Molecule Targeted Anti-cancer Drug Market Size (2019-2030)
10.2 Middle East & Africa Small Molecule Targeted Anti-cancer Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Small Molecule Targeted Anti-cancer Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Small Molecule Targeted Anti-cancer Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astrazeneca
11.1.1 Astrazeneca Company Detail
11.1.2 Astrazeneca Business Overview
11.1.3 Astrazeneca Small Molecule Targeted Anti-cancer Drug Introduction
11.1.4 Astrazeneca Revenue in Small Molecule Targeted Anti-cancer Drug Business (2019-2024)
11.1.5 Astrazeneca Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Small Molecule Targeted Anti-cancer Drug Introduction
11.2.4 Novartis Revenue in Small Molecule Targeted Anti-cancer Drug Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Millennium Pharmaceuticals
11.3.1 Millennium Pharmaceuticals Company Detail
11.3.2 Millennium Pharmaceuticals Business Overview
11.3.3 Millennium Pharmaceuticals Small Molecule Targeted Anti-cancer Drug Introduction
11.3.4 Millennium Pharmaceuticals Revenue in Small Molecule Targeted Anti-cancer Drug Business (2019-2024)
11.3.5 Millennium Pharmaceuticals Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Small Molecule Targeted Anti-cancer Drug Introduction
11.4.4 Bayer Revenue in Small Molecule Targeted Anti-cancer Drug Business (2019-2024)
11.4.5 Bayer Recent Development
11.5 Exelixis
11.5.1 Exelixis Company Detail
11.5.2 Exelixis Business Overview
11.5.3 Exelixis Small Molecule Targeted Anti-cancer Drug Introduction
11.5.4 Exelixis Revenue in Small Molecule Targeted Anti-cancer Drug Business (2019-2024)
11.5.5 Exelixis Recent Development
11.6 Abbvie
11.6.1 Abbvie Company Detail
11.6.2 Abbvie Business Overview
11.6.3 Abbvie Small Molecule Targeted Anti-cancer Drug Introduction
11.6.4 Abbvie Revenue in Small Molecule Targeted Anti-cancer Drug Business (2019-2024)
11.6.5 Abbvie Recent Development
11.7 Boehringer-Ingelheim
11.7.1 Boehringer-Ingelheim Company Detail
11.7.2 Boehringer-Ingelheim Business Overview
11.7.3 Boehringer-Ingelheim Small Molecule Targeted Anti-cancer Drug Introduction
11.7.4 Boehringer-Ingelheim Revenue in Small Molecule Targeted Anti-cancer Drug Business (2019-2024)
11.7.5 Boehringer-Ingelheim Recent Development
11.8 Eisai
11.8.1 Eisai Company Detail
11.8.2 Eisai Business Overview
11.8.3 Eisai Small Molecule Targeted Anti-cancer Drug Introduction
11.8.4 Eisai Revenue in Small Molecule Targeted Anti-cancer Drug Business (2019-2024)
11.8.5 Eisai Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Small Molecule Targeted Anti-cancer Drug Introduction
11.9.4 Pfizer Revenue in Small Molecule Targeted Anti-cancer Drug Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Detail
11.10.2 Bristol-Myers Squibb Business Overview
11.10.3 Bristol-Myers Squibb Small Molecule Targeted Anti-cancer Drug Introduction
11.10.4 Bristol-Myers Squibb Revenue in Small Molecule Targeted Anti-cancer Drug Business (2019-2024)
11.10.5 Bristol-Myers Squibb Recent Development
11.11 Roche
11.11.1 Roche Company Detail
11.11.2 Roche Business Overview
11.11.3 Roche Small Molecule Targeted Anti-cancer Drug Introduction
11.11.4 Roche Revenue in Small Molecule Targeted Anti-cancer Drug Business (2019-2024)
11.11.5 Roche Recent Development
11.12 Bettapharma
11.12.1 Bettapharma Company Detail
11.12.2 Bettapharma Business Overview
11.12.3 Bettapharma Small Molecule Targeted Anti-cancer Drug Introduction
11.12.4 Bettapharma Revenue in Small Molecule Targeted Anti-cancer Drug Business (2019-2024)
11.12.5 Bettapharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
